FGFR4 inhibitors, including BLU-554 and FGR401, have been studied as potential treatments for HCC patients that act by interfering with FGF19–FGFR4 signaling and have achieved promising results in phase I and II clinical trials [17]. Here, FGFR4 is linked to hepatocellular carcinoma.